Several factors are attributed to GBM prognosis, depending on clinical and biological patient parameters, such as age and extent of resection, or based on the characteristics of the tumor at the molecular level, such as IDH mutation or MGMT promoter methylation. This evidence concerns the gene IDH1 and glioblastoma.